Asta-werke Aktiengesellschaft

Asta-werke Aktiengesellschaft, Chemische Fabrik

Asta-werke Aktiengesellschaft, Chemische Farik

Asta Pharma Aktiengesellshaft

Norbert Brock

Gerhard Scheffler

Jorg Pohl

Ulf Niemeyer

Peter Emig

Hans Pohle

Hans-Dieter Lenke

Jurij Stekar

This invention relates to new oxzaphosphorin-4-thio-alkanesulphonic acids and to the neutral salts thereof corresponding to the general formula I ##STR1## and to methods to use such compounds to treat cancer diseases and to produce immunosuppression in humans and animals.

oxazaphosphorin-4-thio alkanesulphonic acids, neutral salts thereof and

This invention relates to new oxazaphosphorin-4-thio-alkanesulphonic acids and to the neutral salts thereof corresponding to the general formula I ##STR1## and to methods to use such compounds to control cancer diseases and to produce immunosuppression in humans and animals.

Oxazaphosphorin-4-thio-alkanesulphonic acids, and neutral salts thereof

The present invention relates to new 4-carbamoyloxy-oxazaphosphorins of the general Formula I ##STR1## as well as to a method for the treatment of malign tumor diseases in humans using such compounds as active agent.

4-carbamoyloxy-oxazaphosphorins

The invention is related to a process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents administered to them against malign tumors, comprising administering a pharmacologically acceptable salt of a mercapto alkane sulfonic acid having the general formula

Process for the treatment of humans suffering from undesired urotoxic

The invention is related to a process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents administered to them against malign tumors, comprising administering a pharmacologically acceptable salt of a dithiodi-(alkane sulfonic acid) having the general formula ##STR1## to the human treated with the cytostatically active alkylating agent, in an amount ranging from 20% of the weight of the alkylating agent to the highest tolerated dosage of the salt of the dithiodi-(alkane sulfonic acid), simultaneously or separately in combination with the alkylating agent.

Process for the treatment of spasmodic conditions in humans by administering a compound of the general formula ##STR1## or a pharmacologically acceptable acid addition salt thereof to a human suffering from such conditions.

Process for the treatment of spasmodic conditions in humans

The present invention is related to new basic enol ethers having the general formula ##STR1## and to the pharmacologically acceptable acid addition salts thereof. The invention is further related to process for the treatment of spasmodic conditions in humans by administering a compound of the above general formula or a pharmacologically acceptable acid addition salt thereof to a human suffering from such conditions.

Growing community of inventors

Bielefeld, Germany

Norbert Brock